<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>Veterinary Clinical Studies</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/941C2E74-C576-49DA-9987-CE40EF8A611D"><gtr:id>941C2E74-C576-49DA-9987-CE40EF8A611D</gtr:id><gtr:name>Pfizer</gtr:name><gtr:address><gtr:line1>235 East 42nd Street</gtr:line1><gtr:postCode>10017</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1FEC8455-7672-42EA-80D0-5C1BE25D6206"><gtr:id>1FEC8455-7672-42EA-80D0-5C1BE25D6206</gtr:id><gtr:firstName>Maura</gtr:firstName><gtr:otherNames>Mary</gtr:otherNames><gtr:surname>Wallace</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/EF904DB6-0838-427D-A513-EBFD09816648"><gtr:id>EF904DB6-0838-427D-A513-EBFD09816648</gtr:id><gtr:firstName>Ted</gtr:firstName><gtr:surname>Hupp</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A1361B0A-5B56-4CE0-850D-E44BF0BB5309"><gtr:id>A1361B0A-5B56-4CE0-850D-E44BF0BB5309</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Argyle</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FF008848%2F1"><gtr:id>60D568C5-4402-40C6-9D40-4AE17AD12F0D</gtr:id><gtr:title>Characterisation of primitive stem cell-like canine cancer cells: identification of therapeutic targets through genomics</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/F008848/1</gtr:grantReference><gtr:abstractText>Cancer has emerged as a major cause of morbidity and mortality in the dog, with an estimated incidence of 1 in 4. Despite advances in conventional chemotherapy and radiation, complete cures for most cancer types remains elusive, the challenge being to develop highly targeted therapies that kill cancer cells but leave normal cells healthy. For decades the scientific community has accepted a model that most cells in the body have the capacity to undergo genetic changes that ultimately result in them becoming cancerous. However, there has been a recent challenge to this model that suggests that the ability to become a cancer cell is restricted to specific tissue stem cells. These cells give rise to cancer stem cells that drive the production of daughter tumour cells. Daughter cells have the potential to be killed by conventional chemotherapy and radiation in contrast to cells with stem cell capabilities, which are largely resistant to such therapies. The implications of this are immense as it suggests that current therapeutic strategies are not targeting the root of the cancer, the cancer stem cell. There is a growing body of evidence that cancer is a true stem cell disease. Researchers in human medicine have identified putative cancer stem cells from a diverse range of cancers such as breast, colon, pancreas and brain. We have recently applied similar methodologies to the dog and identified a sub-set of cells in bone cancer that have stem cell characteristics. This proposal aims to further characterize these cells and will seek to identify novel signalling pathways in these cells that have the potential to be a therapeutic target. This study will inform the veterinary oncology community of potentially new ways to kill cancer cells. Further, it has the potential to inform similar studies in people and help to further advance the field of stem cell biology.</gtr:abstractText><gtr:technicalSummary>For decades the advances in molecular techniques has allowed us to continually dissect the mechanisms of carcinogenesis, most work focusing on the accepted model of multistage carcinogenesis underpinned by progressive genetic changes that drive malignant transformation. In this model, any cell in the body has the potential for malignant transformation. More recently, attention has focused on an alternative model where transformation takes place in a tissue stem cell, becoming a cancer stem cell (CSC) and giving rise to a tumour composed mostly of daughter cancer cells and a small number of CS cells that drive tumour growth and expansion. Proof that cancer stem cells exist as a phenotypically different population of cancer cells requires isolation of different populations of cancer cells and demonstration that one or more groups are efficient at producing tumors while other groups lack this ability. However, these cells cannot be definitively called cancer stem cells until it is possible to demonstrate that a single transplanted cancer cell can give rise to a diverse population of cancer cells within a tumour. Using 'sphere' assays we have isolated cancer cells from cell lines and clinical cases that express markers (e.g. Nanog, Oct 3/4) indicative of a primitive phenotype. We have demonstrated that these cells can be passaged multiple times and are phenotypically distinct from daughter populations. This proposal aims to further characterize these cells in vitro and in vivo. In particular we will evaluate to ability of these cells to form tumours in NOD-SCID mice and use microarray to study specific transcriptomic profiles. Finally, we will use the array data, information from the published canine genome sequence, and RNAi to identify and validate potential targets in these cells for therapeutic intervention</gtr:technicalSummary><gtr:fund><gtr:end>2011-03-16</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2008-03-17</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>392040</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Medical detective Series</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CCCB21B8-CF1B-44A5-A165-CB6AB17F7192</gtr:id><gtr:impact>Talked sparked discussion and debate

Interest in our work from a variety of sources</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Arthur Willis Distinguished Speaker Lecture entitled Can comparative biology inform rational cancer drug development?</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2B4B4E8F-EA94-41D1-8AAD-A4D6EA893A24</gtr:id><gtr:impact>Sparked discussion

Development of early stage collaborations in Canada</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Society of Veterinary Pathology</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9138B2BD-783B-4E6E-BCF0-DCBE7805316D</gtr:id><gtr:impact>Sparked discussion and debate

Requests for information about our work</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Talk, University of Hokkaido, Japan</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4C2E986F-8DF0-4108-A07F-F57F6E8A6532</gtr:id><gtr:impact>Sparked discussion afterwards

Supported development of MOU to provide exchange for postgraduate and undergraduate students</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International Conference UNAM University Mexico City</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0B3C4316-B97B-41E3-948A-B74AF161739E</gtr:id><gtr:impact>&amp;gt; 100 people attended from various international countries. I made two state of the art presentations on stem cell biology and set cells in disease.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>9000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Further funding: Pilot investigation into the in vitro effect of mavacoxib (trocoxil) on canine cancer cell lines</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>Zoetis Animal Health</gtr:fundingOrg><gtr:id>B0A9034B-E71F-455D-9AAE-93C27E4DACBB</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Edinburgh Studentship</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>University of Edinburgh</gtr:fundingOrg><gtr:id>AA35F92C-17C0-47C6-B898-D5E21FC47D2D</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>58000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Daphne Jackson Trust</gtr:department><gtr:description>Returnning Scientist Scheme</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>University of Surrey</gtr:fundingOrg><gtr:id>C3E2EF01-3617-40D4-8245-6217F1EF363C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The work in this grant has a major impact for veterinary medicine. However, more widely it has provided direct evidence that natural cancers in dogs provide a more optimal therapeutic model for the development of cancer treatments in people. One of the key advantages being that it reduces the number of experimental animals being used and may provide a more rapid and reproducible model system in the linear drug development pathway. An example of this is highlighted by the fact that it has led to a key industrial collaboration with an Italian biotechnology company developing drugs for humans. We have recently submitted a major grant to MRC based on using the dog model with this company to develop a new antibody targeted therapy for cancer.</gtr:description><gtr:id>AA531498-5EBD-4BED-B142-B558775E9E14</gtr:id><gtr:impactTypes><gtr:impactType>Societal,Economic</gtr:impactType></gtr:impactTypes><gtr:sector>Healthcare</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>We refined and characterised a number of markers and techniques for purifying cancer stem cells in dogs.We characterised these cells in terms of their resistance to radiation and chemotherapy. From this we identified major differences in DNA damage pathways in these cells which contribute to survival of the cancer.We used array technology to analyse the transcriptional profile of cancer stem cells versus &amp;quot;normal&amp;quot; cancer cells and mesenchymal stem cells. From this we have identified a short list of candidate genes that have the potential to be targeted therapeutically.We identified one specific gene that is massively up-regulated in cancer stem cells in bone cancer in dogs and is of major significance therapeutically. This has implications for the management of cancer in dogs, and also could have an impact on human medicine, specifically the treatment of osteosarcoma in children.

Update as of January 2016. As previously noted we identified a key gene COX-2 which we consider to be very important in tumour initiation. Since the end of the great we secured funding for a PhD student to study the role of COX-2 in tumour initiation. In addition, we secured a Daphne Jackson Fellowship for a scientist returning after significant maternity leave to work on COX-2 in cancer. Additional findings from the microarray study has also identified key pathways in EGFR signalling that are also required in cancer stem cell signalling. We have recently submitted a manuscript for publication (in review) based on these findings.</gtr:description><gtr:exploitationPathways>These finding will have an implication for the veterinary healthcare sector. The papers we have already published have gained a lot of interest (downloads and cites) and it will support a greater understanding of basic mechanisms of cancer in veterinary species (and potentially the role of these genes in pluripotency). Interestingly, much of our data implicates the products of these genes playing a major role in the effects of conventional treatments (chemotherapy and radiation) and could have a more direct impact on how we manage veterinary patients. Equally, this information is important for human medicine.</gtr:exploitationPathways><gtr:id>CDF82126-D6B8-4C18-9225-2DF976B12AE4</gtr:id><gtr:sectors><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/40649AC4-504A-4BAE-B5D7-15380A46B1DE"><gtr:id>40649AC4-504A-4BAE-B5D7-15380A46B1DE</gtr:id><gtr:title>From Viruses to Cancer Stem Cells Comparative Oncology Underpinning the One Health Agenda</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/183ca28c8b5adc9d5a7bbfcba635885e"><gtr:id>183ca28c8b5adc9d5a7bbfcba635885e</gtr:id><gtr:otherNames>David Argyle (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/52B47D05-B66B-43BD-972E-5989B6D3EF8D"><gtr:id>52B47D05-B66B-43BD-972E-5989B6D3EF8D</gtr:id><gtr:title>Global gene expression analysis of canine osteosarcoma stem cells reveals a novel role for COX-2 in tumour initiation.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ca3ce1774e252938db32cdecaa5b012c"><gtr:id>ca3ce1774e252938db32cdecaa5b012c</gtr:id><gtr:otherNames>Pang LY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/62F1D573-4F0F-4B87-BD81-DC8F7500DC1A"><gtr:id>62F1D573-4F0F-4B87-BD81-DC8F7500DC1A</gtr:id><gtr:title>Feline mammary carcinoma stem cells are tumorigenic, radioresistant, chemoresistant and defective in activation of the ATM/p53 DNA damage pathway.</gtr:title><gtr:parentPublicationTitle>Veterinary journal (London, England : 1997)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ca3ce1774e252938db32cdecaa5b012c"><gtr:id>ca3ce1774e252938db32cdecaa5b012c</gtr:id><gtr:otherNames>Pang LY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1090-0233</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2729478D-0169-4CE1-999A-56BDE2F12EFA"><gtr:id>2729478D-0169-4CE1-999A-56BDE2F12EFA</gtr:id><gtr:title>Cancer stem cells and telomerase as potential biomarkers in veterinary oncology.</gtr:title><gtr:parentPublicationTitle>Veterinary journal (London, England : 1997)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ca3ce1774e252938db32cdecaa5b012c"><gtr:id>ca3ce1774e252938db32cdecaa5b012c</gtr:id><gtr:otherNames>Pang LY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1090-0233</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1A78E71E-2AA3-4C54-B593-F5591FC3C60D"><gtr:id>1A78E71E-2AA3-4C54-B593-F5591FC3C60D</gtr:id><gtr:title>Feline mammary carcinoma stem cells are tumorigenic, radioresistant, chemoresistant and defective in activation of the ATM/p53 DNA damage pathway.</gtr:title><gtr:parentPublicationTitle>Veterinary journal (London, England : 1997)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ca3ce1774e252938db32cdecaa5b012c"><gtr:id>ca3ce1774e252938db32cdecaa5b012c</gtr:id><gtr:otherNames>Pang LY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:isbn>1090-0233</gtr:isbn><gtr:issn>1090-0233</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/82980550-CA8A-45DD-97D8-9301C7CA7DBF"><gtr:id>82980550-CA8A-45DD-97D8-9301C7CA7DBF</gtr:id><gtr:title>Low-Density Lipoprotein Uptake Demonstrates a Hepatocyte Phenotype in the Dog, but Is Nonspecific.</gtr:title><gtr:parentPublicationTitle>Stem cells and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0ea58fbb661e0582791972558bb4552f"><gtr:id>0ea58fbb661e0582791972558bb4552f</gtr:id><gtr:otherNames>Gow AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1547-3287</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D92E526E-F84A-4F40-B253-E4DCC6C22BFA"><gtr:id>D92E526E-F84A-4F40-B253-E4DCC6C22BFA</gtr:id><gtr:title>Using naturally occurring tumours in dogs and cats to study telomerase and cancer stem cell biology.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ca3ce1774e252938db32cdecaa5b012c"><gtr:id>ca3ce1774e252938db32cdecaa5b012c</gtr:id><gtr:otherNames>Pang LY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AF1DED4E-D7F4-4227-AA67-3621CC912497"><gtr:id>AF1DED4E-D7F4-4227-AA67-3621CC912497</gtr:id><gtr:title>Veterinary oncology: Biology, big data and precision medicine.</gtr:title><gtr:parentPublicationTitle>Veterinary journal (London, England : 1997)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ca3ce1774e252938db32cdecaa5b012c"><gtr:id>ca3ce1774e252938db32cdecaa5b012c</gtr:id><gtr:otherNames>Pang LY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1090-0233</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DC2688F4-B679-45F2-B73E-222CC4D1B474"><gtr:id>DC2688F4-B679-45F2-B73E-222CC4D1B474</gtr:id><gtr:title>The long-acting COX-2 inhibitor mavacoxib (Trocoxil?) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro.</gtr:title><gtr:parentPublicationTitle>BMC veterinary research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ca3ce1774e252938db32cdecaa5b012c"><gtr:id>ca3ce1774e252938db32cdecaa5b012c</gtr:id><gtr:otherNames>Pang LY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1746-6148</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3F729F2F-7115-479E-A780-511CA6836B20"><gtr:id>3F729F2F-7115-479E-A780-511CA6836B20</gtr:id><gtr:title>The evolving cancer stem cell paradigm: implications in veterinary oncology.</gtr:title><gtr:parentPublicationTitle>Veterinary journal (London, England : 1997)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ca3ce1774e252938db32cdecaa5b012c"><gtr:id>ca3ce1774e252938db32cdecaa5b012c</gtr:id><gtr:otherNames>Pang LY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1090-0233</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DB8FD9C3-0501-44C9-B3F4-B20BB8B61B4A"><gtr:id>DB8FD9C3-0501-44C9-B3F4-B20BB8B61B4A</gtr:id><gtr:title>Canine mammary cancer cells direct macrophages toward an intermediate activation state between M1/M2.</gtr:title><gtr:parentPublicationTitle>BMC veterinary research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7727fe44902b8fb2e9545e38e878e418"><gtr:id>7727fe44902b8fb2e9545e38e878e418</gtr:id><gtr:otherNames>Beir?o BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1746-6148</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FCD13BC7-D844-451C-978B-66C3DC30C531"><gtr:id>FCD13BC7-D844-451C-978B-66C3DC30C531</gtr:id><gtr:title>Canine and Feline Cancer Stem Cells in Comparative Oncology Research</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/183ca28c8b5adc9d5a7bbfcba635885e"><gtr:id>183ca28c8b5adc9d5a7bbfcba635885e</gtr:id><gtr:otherNames>David Argyle (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6C6064AE-A0A9-464C-A704-E46DB6FB16FA"><gtr:id>6C6064AE-A0A9-464C-A704-E46DB6FB16FA</gtr:id><gtr:title>Cyclooxygenase-2: A Role in Cancer Stem Cell Survival and Repopulation of Cancer Cells during Therapy.</gtr:title><gtr:parentPublicationTitle>Stem cells international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ca3ce1774e252938db32cdecaa5b012c"><gtr:id>ca3ce1774e252938db32cdecaa5b012c</gtr:id><gtr:otherNames>Pang LY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/99B133F8-F924-4CD7-8CED-3C7C54B2F66C"><gtr:id>99B133F8-F924-4CD7-8CED-3C7C54B2F66C</gtr:id><gtr:title>Canines and Cancer Stem Cells: Dogs Helping Transform Human Cancer Practice</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/183ca28c8b5adc9d5a7bbfcba635885e"><gtr:id>183ca28c8b5adc9d5a7bbfcba635885e</gtr:id><gtr:otherNames>David Argyle (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/290A3C13-BC12-492F-A785-C0EFB3A08092"><gtr:id>290A3C13-BC12-492F-A785-C0EFB3A08092</gtr:id><gtr:title>Biomarkers and Stem Cells: Translating discovery to clinical practice</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/183ca28c8b5adc9d5a7bbfcba635885e"><gtr:id>183ca28c8b5adc9d5a7bbfcba635885e</gtr:id><gtr:otherNames>David Argyle (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/F008848/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>